Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Deeksha Madhry, Shivani Malvankar, Sushant Phadnis, Rupesh K. Srivastava, Sankar Bhattacharyya & Bhupendra Verma. (2023) Synergistic correlation between host angiogenin and dengue virus replication. RNA Biology 20:1, pages 805-816.
Read now
Read now
Thomas Schirrmann, André Frenzel, Lars Linden, Beatrix Stelte-Ludwig, Jörg Willuda, Axel Harrenga, Stefan Dübel, Beate Müller-Tiemann & Mark Trautwein. (2014) Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform. mAbs 6:2, pages 367-380.
Read now
Read now
Andrea L.J. Marschall, André Frenzel, Thomas Schirrmann, Manuela Schüngel & Stefan Dubel. (2011)
Targeting antibodies to the cytoplasm
. mAbs 3:1, pages 3-16.
Read now
Read now
Articles from other publishers (44)
Hongyan Cui, Ming Zhang, Liuwei Zhang, Haidong Li, Yue Wang, Yan Zhao, Qixian Chen & Jingyun Wang. (2023) pH-responsive organic/inorganic hybrid nanocolloids for transcellular delivery of ribonucleolytic payloads toward targeted anti-glioma therapy. Journal of Colloid and Interface Science 634, pages 388-401.
Crossref
Crossref
Sheng-Yan Yin, Yingcai Hu, Jing Zheng, Jishan Li & Ronghua Yang. (2022) Tannic Acid-Assisted Biomineralization Strategy for Encapsulation and Intracellular Delivery of Protein Drugs. ACS Applied Materials & Interfaces 14:45, pages 50583-50591.
Crossref
Crossref
Patrizia Cioni, Edi Gabellieri, Barbara Campanini, Stefano Bettati & Samanta Raboni. (2022) Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications. Current Medicinal Chemistry 29:3, pages 411-452.
Crossref
Crossref
Mohammadreza Nassiri, Reihane Behnam-Rasouli, Masoume Vakili-Azghandi, Vinod Gopalan, Peyman Dolati & Rouhollah Nourmohammadi. (2022) Refined immunoRNases for the efficient targeting and selective killing of tumour cells: A novel strategy. Life Sciences 289, pages 120222.
Crossref
Crossref
Jessica Castro, Marc Ribó, Maria Vilanova & Antoni Benito. (2021) Strengths and Challenges of Secretory Ribonucleases as AntiTumor Agents. Pharmaceutics 13:1, pages 82.
Crossref
Crossref
Manuel Lasch, Konda Kumaraswami, Simona Nasiscionyte, Susanna Kircher, Dominic van den Heuvel, Sarah Meister, Hellen Ishikawa-Ankerhold & Elisabeth Deindl. (2020) RNase A Treatment Interferes With Leukocyte Recruitment, Neutrophil Extracellular Trap Formation, and Angiogenesis in Ischemic Muscle Tissue. Frontiers in Physiology 11.
Crossref
Crossref
Ali Forouharmehr, Mohammadreza Nassiri, Shahrokh Ghovvati Roudsari & Ali Javadmanesh. (2019) Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1‐positive cell lines. Journal of Cellular Physiology 235:5, pages 4679-4687.
Crossref
Crossref
Manuel LaschEike Christian KleinertSarah Meister, Konda KumaraswamiJudith-Irina BuchheimTobias GrantzowThomas LautzSofia SalpistiSilvia FischerKerstin TroidlIngrid Fleming, Anna M. Randi, Markus Sperandio, Klaus T. PreissnerElisabeth Deindl. (2019) Extracellular RNA released due to shear stress controls natural bypass growth by mediating mechanotransduction in mice. Blood 134:17, pages 1469-1479.
Crossref
Crossref
Neelakshi Mungra, Sandra Jordaan, Precious Hlongwane, Krupa Naran, Shivan Chetty & Stefan Barth. (2019) Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells. Oncotarget 10:8, pages 897-915.
Crossref
Crossref
Xenia Wezler, Stefan Dübel & Thomas Schirrmann. (2018) Antibody fusion proteins with human ribonucleases 1 to 8. Human Antibodies 26:4, pages 177-192.
Crossref
Crossref
Sandra Jordaan, Olusiji Akinrinmade, Thomas Nachreiner, Christian Cremer, Krupa Naran, Shivan Chetty & Stefan Barth. (2018) Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells. Biomedicines 6:1, pages 28.
Crossref
Crossref
Joerg Schmohl, Deborah Todhunter, Elizabeth Taras, Veronika Bachanova & Daniel Vallera. (2018) Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies. Toxins 10:1, pages 32.
Crossref
Crossref
Elio Pizzo, Rosario Oliva, Rita Morra, Andrea Bosso, Sara Ragucci, Luigi Petraccone, Pompea Del Vecchio & Antimo Di Maro. (2017) Binding of a type 1 RIP and of its chimeric variant to phospholipid bilayers: evidence for a link between cytotoxicity and protein/membrane interactions. Biochimica et Biophysica Acta (BBA) - Biomembranes 1859:10, pages 2106-2112.
Crossref
Crossref
Xiaowen Liu, Peng Zhang, Wolfgang Rödl, Kevin Maier, Ulrich Lächelt & Ernst Wagner. (2016) Toward Artificial Immunotoxins: Traceless Reversible Conjugation of RNase A with Receptor Targeting and Endosomal Escape Domains. Molecular Pharmaceutics 14:5, pages 1439-1449.
Crossref
Crossref
Thomas Hodge, Ken Draper, Trevor Brasel, Alexander Freiberg, Luis Squiquera, David Sidransky, Jamie Sulley & Debra J. Taxman. (2016) Antiviral effect of ranpirnase against Ebola virus. Antiviral Research 132, pages 210-218.
Crossref
Crossref
Xiaojing Cong, Christian Cremer, Thomas Nachreiner, Stefan Barth & Paolo Carloni. (2016) Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations. Protein Science 25:8, pages 1451-1460.
Crossref
Crossref
Vadim Sergeevich Pokrovskii, E.M. Treshchalina, N.V. Andronova & S.M. Deev. (2016) Ribonucleases with Antiproliferative Properties: Molecular Biological and Biochemical Characteristics. Clinical oncohematology 9:2, pages 130-137.
Crossref
Crossref
Peng Zhang, Dongsheng He, Philipp Michael Klein, Xiaowen Liu, Ruth Röder, Markus Döblinger & Ernst Wagner. (2015) Enhanced Intracellular Protein Transduction by Sequence Defined Tetra-Oleoyl Oligoaminoamides Targeted for Cancer Therapy. Advanced Functional Materials 25:42, pages 6627-6636.
Crossref
Crossref
Elena M. Glinka. (2015) Killing of cancer cells through the use of eukaryotic expression vectors harbouring genes encoding nucleases and ribonuclease inhibitor. Tumor Biology 36:5, pages 3147-3157.
Crossref
Crossref
Inés Fernández-Ulibarri, Katharina Hammer, Michaela A.E. Arndt, Johanna K. Kaufmann, Dominik Dorer, Sarah Engelhardt, Roland E. Kontermann, Jochen Hess, Heike Allgayer, Jürgen Krauss & Dirk M. Nettelbeck. (2015) Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. International Journal of Cancer 136:9, pages 2228-2240.
Crossref
Crossref
Stefan Kiesgen, Michaela A.E. Arndt, Christoph Körber, Ulrich Arnold, Tobias Weber, Niels Halama, Armin Keller, Benedikt Bötticher, Anne Schlegelmilch, Nora Liebers, Martin Cremer, Christel Herold-Mende, Gerhard Dyckhoff, Philippe A. Federspil, Alexandra D. Jensen, Dirk Jäger, Roland E. Kontermann, Walter Mier & Jürgen Krauss. (2015) An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo. Cancer Letters 357:1, pages 364-373.
Crossref
Crossref
Thomas Schirrmann, Miriam Steinwand, Xenia Wezler, Andre ten Haaf, Mehmet K. Tur & Stefan Barth. (2013) CD30 as a Therapeutic Target for Lymphoma. BioDrugs 28:2, pages 181-209.
Crossref
Crossref
Martin Siegemund, Fabian Richter, Oliver Seifert, Felix Unverdorben & Roland E. Kontermann. 2014. Monoclonal Antibodies. Monoclonal Antibodies
273
295
.
Ester Boix, Jose A. Blanco, M. Victòria Nogués & Mohammed Moussaoui. (2013) Nucleotide binding architecture for secreted cytotoxic endoribonucleases. Biochimie 95:6, pages 1087-1097.
Crossref
Crossref
Wojciech Ardelt. 2013. Fusion Protein Technologies for Biopharmaceuticals. Fusion Protein Technologies for Biopharmaceuticals
337
353
.
Stefan Barth, Stefan Gattenlöhner & Mehmet Kemal Tur. 2013. Fusion Protein Technologies for Biopharmaceuticals. Fusion Protein Technologies for Biopharmaceuticals
329
336
.
Sonja Schiffer, Dmitrij Hristodorov, Radoslav Mladenov, Eric Aslanian, Michael Huhn, Rainer Fischer, Stefan Barth & Theo Thepen. (2013) Species-Dependent Functionality of the Human Cytolytic Fusion Proteins Granzyme B-H22(scFv) and H22(scFv)-Angiogenin in Macrophages. Antibodies 2:4, pages 9-18.
Crossref
Crossref
Christian Kellner & Matthias Peipp. 2013. Molecular and Cellular Mechanisms of Antibody Activity. Molecular and Cellular Mechanisms of Antibody Activity
251
284
.
Miriam Wöhner, Stefanie Born & Lars Nitschke. (2012) Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model. European Journal of Immunology 42:11, pages 3009-3018.
Crossref
Crossref
Jaime Tomé-Amat, Aida Menéndez-Méndez, Lucía García-Ortega, Carl A. Batt, Mercedes Oñaderra, Álvaro Martínez-del-Pozo, José G. Gavilanes & Javier Lacadena. (2012) Production and characterization of scFvA33T1, an immunoRNase targeting colon cancer cells. FEBS Journal 279:17, pages 3022-3032.
Crossref
Crossref
N. Carreras-Sangra, J. Tome-Amat, L. Garcia-Ortega, C. A. Batt, M. Onaderra, A. Martinez-del-Pozo, J. G. Gavilanes & J. Lacadena. (2012) Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin -sarcin. Protein Engineering Design and Selection 25:8, pages 425-435.
Crossref
Crossref
Jae H. Park & Ross L. Levine. (2012) Targeted Immunotherapy for Hairy Cell Leukemia. Journal of Clinical Oncology 30:15, pages 1888-1890.
Crossref
Crossref
Vera Ulyanova, Valentina Vershinina & Olga Ilinskaya. (2011) Barnase and binase: twins with distinct fates. FEBS Journal 278:19, pages 3633-3643.
Crossref
Crossref
Pere Tubert, Montserrat Rodríguez, Marc Ribó, Antoni Benito & Maria Vilanova. (2010) The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity. Investigational New Drugs 29:5, pages 811-817.
Crossref
Crossref
C. Kellner, W.K. Bleeker, J.J. Lammerts van Bueren, M. Staudinger, K. Klausz, S. Derer, P. Glorius, A. Muskulus, B.E.C.G. de Goeij, J.G.J. van de Winkel, P.W.H.I. Parren, T. Valerius, M. Gramatzki & M. Peipp. (2011) Human kappa light chain targeted Pseudomonas exotoxin A — identifying human antibodies and Fab fragments with favorable characteristics for antibody–drug conjugate development. Journal of Immunological Methods 371:1-2, pages 122-133.
Crossref
Crossref
Swati Choudhary, Mrudula Mathew & Rama S. Verma. (2011) Therapeutic potential of anticancer immunotoxins. Drug Discovery Today 16:11-12, pages 495-503.
Crossref
Crossref
Holger Thie, Lars Toleikis, Jiandong Li, Reinhard von Wasielewski, Gunther Bastert, Thomas Schirrmann, Isabel Tourais Esteves, Christian K. Behrens, Bénédict Fournes, Nathalie Fournier, Christophe de Romeuf, Michael Hust & Stefan Dübel. (2011) Rise and Fall of an Anti-MUC1 Specific Antibody. PLoS ONE 6:1, pages e15921.
Crossref
Crossref
Evandro Fei Fang & Tzi Bun Ng. (2011) Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1815:1, pages 65-74.
Crossref
Crossref
Marc Ribó, Antoni Benito & Maria Vilanova. 2011. Ribonucleases. Ribonucleases
55
88
.
Chien-Hsing Chang, Pankaj Gupta, Rosana Michel, Meiyu Loo, Yang Wang, Thomas M. Cardillo & David M. Goldenberg. (2010) Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells. Molecular Cancer Therapeutics 9:8, pages 2276-2286.
Crossref
Crossref
Daniel A. Vallera, Seunguk Oh, Hua Chen, Yanqun Shu & Arthur E. Frankel. (2010) Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases. Molecular Cancer Therapeutics 9:6, pages 1872-1883.
Crossref
Crossref
Humberto González-Díaz, María A. Dea-Ayuela, Lázaro G. Pérez-Montoto, Francisco J. Prado-Prado, Guillermín Agüero-Chapín, Francisco Bolas-Fernández, Roberto I. Vazquez-Padrón & Florencio M. Ubeira. (2009) QSAR for RNases and theoretic–experimental study of molecular diversity on peptide mass fingerprints of a new Leishmania infantum protein. Molecular Diversity 14:2, pages 349-369.
Crossref
Crossref
Torsten Rülker, Doris Meier & Thomas Schirrmann. 2010. Antibody Engineering. Antibody Engineering
743
748
.
S. M. Deev & E. N. Lebedenko. (2009) Antibody engineering: Molecular constructor on the basis of barnase-barstar module. Russian Journal of Bioorganic Chemistry 35:6.
Crossref
Crossref